Deals this week: Insulet Corporation, Hancock Jaffe Laboratories, Avinger

10 November 2017 (Last Updated November 9th, 2017 11:39)

Insulet Corporation plans to raise $300m through the private placement of convertible senior notes due in 2024.

Insulet Corporation plans to raise $300m through the private placement of convertible senior notes due in 2024.

The US-based company plans to use the funds for general corporate purposes.

Hancock Jaffe Laboratories Inc has announced an initial public offering (IPO) of one million shares of its common stock priced between $6 and $8 a share to raise up to $15m.

The US-based medical device firm plans to use the stocks for research and development activities, as well as other general corporate purposes.

US-based Avinger Inc plans to raise $15m through the private placement of shares of its common stock.

The company plans to use the funds for working capital and general corporate purposes.

“Takeda Pharmaceutical Co Ltd has signed an agreement to develop and market Portal Instruments Inc’s needle-free drug delivery device.”

Takeda Pharmaceutical Co Ltd has signed an agreement to develop and market Portal Instruments Inc’s needle-free drug delivery device, which is planned to be used with Takeda’s investigational or approved drugs.

As part of the agreement, Takeda will make an initial payment to Portal and additional payments of up to $100m upon achieving certain development milestones.

Takeda is a Japanese pharmaceutical company, whereas Portal is a medical device company based in the US.